The pharmaceutical company's shares have seen an increase of 1.87% over the last month, surpassing the Medical sector's gain of 0.71% and falling behind the S&P 500's gain of 3.82%. Investors should also note any recent changes to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. The Zacks Rank system, running from #1 (Strong Buy) to #5 (St ...

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Organon possesses a Zacks Rank of #3 (Hold). Organon (OGN) ended the recent trading session at $19.93, demonstrating a -1.04% swing from the preceding day's closing price. This change lagged the S&P 500's 0.07% gain o ...

In the latest market close, Organon (OGN) reached $20.63, with a -0.77% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.04%, and the technology-centric Nasdaq increased by 0.49%. Prior to today's trading, shares of the pharmaceutical company had lost 0.91% over the past month. This has lagged the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. The upcoming earnings rel ...

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as w ...

Core Viewpoint - Investors should monitor recent shifts in analyst projections for Organon, as these modifications often indicate changing near-term business trends and reflect analyst optimism about the company's profitability [1] Company Performance - Organon's shares have decreased by 7.33% over the last month, underperforming the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59% [2] - The latest trading session saw Organon ending at $20.45, marking a +0.49% adjustment from the previous day's close, outperforming the S&P 500's daily loss of 0.25% [7] Earnings Estimates - The full-year Zacks Consensus Estimates for Organon project earnings of $4.42 per share and revenue of $6.37 billion, representing year-over-year changes of +6.76% and +1.67%, respectively [3] - The upcoming earnings release is expected to show an EPS of $1.18, indicating a 9.92% decline compared to the same quarter last year, with revenue estimated at $1.63 billion, up 1.16% from the prior-year quarter [8] Valuation Metrics - Organon currently has a PEG ratio of 0.86, compared to the Medical Services industry's average PEG ratio of 1.53 [5] - The company holds a Forward P/E ratio of 4.6, which is a discount compared to the industry's average Forward P/E of 19.08 [10] Industry Ranking - The Medical Services industry, which includes Organon, has a Zacks Industry Rank of 96, placing it in the top 39% of over 250 industries [11]

Last Reported Results and Surprise History Over the past month, shares of this pharmaceutical company have returned -5.1%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 0.9%. The key question now is: What could be the stock's future direction? Revisions to Earnings Estimates We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the la ...

Group 1 - Organon (OGN) has recently reached a key level of support and has overtaken the 20-day moving average, indicating a short-term bullish trend [1] - The 20-day simple moving average (SMA) is a popular tool among traders as it smooths out price fluctuations and can signal trend reversals more effectively than longer-term averages [2] - OGN has rallied 8.8% over the past four weeks and currently holds a Zacks Rank 1 (Strong Buy), suggesting potential for further upward movement [3] Group 2 - Positive earnings estimate revisions support the bullish outlook for OGN, with no estimates decreasing in the past two months and three estimates increasing [3] - The combination of earnings estimate revisions and technical indicators suggests that investors should monitor OGN for potential gains in the near future [4]

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned +9.2% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has lost 2.8% over this period. Now the key question is: Where could the stock be headed in the near term? Although media repo ...

Organon (OGN) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. The upward trend in estimate revisions for this pharmaceutical company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between ...

Which Healthcare Company Is Best? Joe Raedle/Getty Images News Organon (NYSE:OGN) and Pfizer (PFE) both yield over 5% and are the two highest yielding pharmaceuticals. Bristol-Myers (BMY) is the only other pharmaceutical company that offers a yield above 5% that like Organon and Pfizer, can compete with similarly yielding Treasuries (i.e., those with maturities 12 months or less). Three troubling years of declining double-digit annualized returns have resulted in these well-above average yields. Pfizer ha ...